Eric Bolesh
Eric Bolesh
among balance companies critical desirable develop early loss options practical pursue range revenue risk secondary
Companies must balance their options among the most desirable and most practical strategies. While R&D may develop a next-generation brand, companies risk early loss of critical revenue streams if they do not pursue a range of secondary and tertiary options.
advances benefits competition early gained generation generic given goals launch market outweigh patients plan product ready realistic savings scientific setting start switching
Setting realistic goals and having a well-thought-out plan is important. Generic competition in any given market is inevitable. Start your next- generation drug development early -- just after product launch -- and be ready to show patients that the benefits gained from the scientific advances of a next-generation drug outweigh the savings that come from switching to generics.